The discoveries of EGFR mutations and ALK rearrangements as actionable oncogenic
drivers in non-small-cell lung cancer (NSCLC) has propelled a biomarker-directed treatment …

CNS tumors remain among the deadliest forms of cancer, resisting conventional and new
treatment approaches, with mortality rates staying practically unchanged over the past 30 …

The discovery that mutations in the EGFR gene are detected in up to 50% of lung
adenocarcinoma patients, along with the development of highly efficacious epidermal …

PURPOSE We report CNS efficacy of first-line osimertinib plus chemotherapy versus
osimertinib monotherapy in patients with epidermal growth factor receptor (EGFR)–mutated …

Background Clinical guidelines advise osimertinib as preferred first line treatment for
advanced epidermal growth factor receptor (EGFR) mutated non-small cell lung cancer …

Importance Non–small cell lung cancer (NSCLC) with uncommonEGFRmutations is a rare
subgroup, composing 14% of allEGFRmutations. Objective To determine the usefulness of …

New mass spectrometry imaging (MSI) techniques are gaining importance in various stages
of the drug discovery and development chain as well as in more fundamental studies of drug …

Many researchers are attempting to identify drugs that can be repurposed as effective
therapies for Alzheimer's disease (AD). Several recent studies have highlighted epidermal …

The altered activation or overexpression of protein kinases (PKs) is a major subject of
research in oncology and their inhibition using small molecules, protein kinases inhibitors …

The improved survival outcomes of patients with non-small-cell lung cancer (NSCLC),
largely owing to the improved control of systemic disease provided by immune-checkpoint …